The UK’s plans to leave the European Union (EU) and the EU’s single market could have serious
implications for patients’ access to medicines and medical technologies.
The Brexit Health Alliance has released a briefing that explores how UK and EU citizens could be affected by the disruption in trade that could result from the UK’s exit from the EU, as well as in the event of lack of cooperation in the regulation of medicines and devices between the EU and the UK post Brexit.
The briefing includes a series of case studies, as well as calling for a series of actions to protect patients:
• No negative impact on patients.
• Patient safety and public health to be guaranteed post Brexit.
• Pragmatic solutions allowing patients and the public to benefit from the UK’s participation in EU systems.
• An implementation period beyond the two years of Article 50 negotiations (which end in March 2019).
You can find the full briefing here.